Tariffs on medical devices would push up prices and disrupt research and development efforts at the expense of US patients, ...
ResMed faces an uncertain future as GLP-1 weight loss drugs threaten to reduce demand for sleep apnea devices, creating a complex investment dilemma for shareholders of the CPAP machine leader.
ResMed (NYSE:RMD) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates ...
SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Thursday reported fiscal first-quarter net income of $348.5 million. On a per-share basis, the San Diego-based company said it had net income of ...
Resmed Inc.’s RMD adjusted earnings per share (EPS) in the first quarter of fiscal 2026 were $2.55, up 15.9% year over year. The metric beat the Zacks Consensus Estimate by 2.41%. The adjustments ...
Australian shares are poised to rise on Friday following a landmark US-China summit in which leaders US President Donald Trump and Chinese President Xi Jinping agreed to extend a tariff truce, roll ...
Hosted on MSN
Morgan Stanley Maintains ResMed Inc. - Depositary Receipt (RSMDF) Overweight Recommendation
Fintel reports that on October 21, 2025, Morgan Stanley maintained coverage of ResMed Inc. - Depositary Receipt (OTCPK:RSMDF) with a Overweight recommendation. Analyst Price Forecast Suggests 51.00% ...
TipRanks on MSN
ResMed CFO Reports Stock Transactions Under Rule 10b5-1 Plan
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( ($AU:RMD) ) has shared an update. ResMed Inc.’s Chief Financial Officer, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback